Deerfield Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Deerfield Management’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-3,514,084	Closed	-$62.4M	–	117
2018 Q3	$62.4M	Buy	3,514,084 +1,189,785	+51%	+$20.4M	2.24%	12
2018 Q2	$32.1M	Sell	2,324,299 -303,241	-12%	-$3.6M	1.13%	34
2018 Q1	$23.9M	Buy	+2,627,540	New	+$14.5M	0.83%	47
2014 Q1	–	Sell	-111,967	Closed	-$1.2M	–	147
2013 Q4	$1.2M	Buy	111,967 +61,537	+122%	+$679K	0.06%	94
2013 Q3	$672K	Buy	50,430 +22,722	+82%	+$359K	0.03%	106
2013 Q2	$364K	Buy	+27,708	New	+$374K	0.02%	109

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $830M AUM 21.8% 1-Year Est. Return

Deerfield Management's ECYT Position: Q4 2018 in Review

Deerfield Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 3,514,084 shares — an estimated $62.4M sold.

Deerfield Management first reported a position in ECYT in Q2 2013 and held it in 6 quarters. The position peaked at $62.4M in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

Deerfield Management reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Deerfield Management sold 3,514,084 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $62.4M.
Deerfield Management first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 6 quarters.
Deerfield Management's Endocyte, Inc. Common Stock position peaked at $62.4M in Q3 2018.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Deerfield Management's 13F filing for Q4 2018, filed 14 Feb 2019.